Evidence map›Paper›PMID 34638537›Full record

ArticleInternational journal of molecular sciences2021

Cyclosporine A Protects Retinal Explants against Hypoxia.

Sven Schnichels, Maximilian Schultheiss, Patricia Klemm, Matthias Blak, Thoralf Herrmann, Marion Melchinger, Karl-Ulrich Bartz-Schmidt, Marina Löscher, Günther Zeck, Martin Stehphan Spitzer and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Sven SchnichelsCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Maximilian SchultheissClinic for Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany.
Patricia KlemmCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Matthias BlakCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Thoralf HerrmannNMI Natural and Medical Sciences Institute, University of Tübingen, 72770 Reutlingen, Germany.
Marion MelchingerCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Karl-Ulrich Bartz-SchmidtCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Marina LöscherCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.
Günther ZeckInstitute of Electrodynamics, Microwave and Circuit Engineering, TU Wien, 1040 Vienna, Austria.
Martin Stehphan SpitzerCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-4588-1767
José HurstCentre for Ophthalmology Tübingen, University Eye Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-8697-2569
STZ eyetrial · DEUniversität Hamburg · DENatural and Medical Sciences Institute · DETU Wien · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retina is a complex neurological tissue and is extremely sensitive to an insufficient supply of oxygen. Hypoxia plays a major role in several retinal diseases, and often results in the loss of cells that are essential for vision. Cyclosporine A (CsA) is a widely used immunosuppressive drug. Furthermore, treatment with CsA has neuroprotective effects in several neurologic disorders. No data are currently available on the tolerated concentration of CsA when applied to the retina. To reveal the most effective dose, retinal explants from rat eyes were exposed to different CsA concentrations (1-9 µg/mL). Immunohistochemistry with brain-specific homeobox/POU domain protein 3a (Brn3a) and TUNEL staining was performed to determine the percentage of total and apoptotic retinal ganglion cells (RGCs), as well as the responses of micro- and macroglial cells. Furthermore, optical coherence tomography (OCT) scans were performed to measure the changes in retinal thickness, and recordings with multielectrode array (MEA) were performed to evaluate spontaneous RGC spiking. To examine the neuroprotective effects, retinas were subjected to a hypoxic insult by placing them in a nitrogen-streamed hypoxic chamber prior to CsA treatment. In the biocompatibility tests, the different CsA concentrations had no negative effect on RGCs and microglia. Neuroprotective effects after a hypoxic insult on RGCs was demonstrated at a concentration of 9 µg/mL CsA. CsA counteracted the hypoxia-induced loss of RGCs, reduced the percentage of TUNEL

Indexed as

AnimalsApoptosisCell HypoxiaCell LineCell SurvivalCyclosporineGlaucomaNeuroprotective AgentsOrgan Culture TechniquesRatsRetinaRetinal DiseasesRetinal Ganglion CellsRetinal Vein OcclusionTomography, Optical CoherenceCyclosporineNeuroprotective Agentscyclosporine Ahypoxiaischemianeuroprotectionretinal ganglion cells

Identifiers

PMID34638537
PMCPMC8508578
OpenAlexW3201853012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.